A pre-clinical stage company, Artus Therapeutics is structured around developing first-in-class therapeutics for inflammatory and metabolic diseases by targeting barrier dysfunction with an initial focus on inflammatory bowel disease. Currently housed in the Harvard Pagliuca Life Lab, the company offers a unique drug design and development platform that - it is suggested - has the potential to transform the treatment paradigm for barrier dysfunction diseases, enabling patients to maintain a healthy gut barrier.
